Welcome to MolDiag-PaCa
Advalytix AG
>> Publications

Advalytix (www.advalytix.de) develops incubation stations for both DNA and protein microarrays. The key components of these instruments are the microagitation chips which the company manufactures in its own state-of-the-art clean room. Further expertise lies in PCR, clinical and immuno-chemistry as well as in innovative lab-on-the-chip development.


Role in the Integrated Project:

Advalytix will develop special incubation and washing stations for the diagnostic microarrays investigated in workpackages 4 and 5 and support the optimization of the biological protocols using these instruments. The reproducibility achieved by automating the incubation and washing steps using state of the art technology will be important for the validation of preclinical studies. The optimization of the protocols will be done in close cooperation with the participants of WP 4 and 5.


Research group members involved:
  • Dr. Matthias Wassermeier: head of system development
  • Dr. Zeno von Guttenberg: senior researcher

Contact:
Eugen Sänger Ring 4
85649 Brunnthal
Tel.: +49 89 62836641
fax.: +49 89 62836610
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
homepage: www.advalytix.de


>> Publications



Professor Nick R Lemoine
MD PhD FRCPath FMedSci
Director of the Institute of Cancer
Centre Lead, Molecular Oncology

Dr Tatjana Crnogorac-Jurcevic
MD PhD
Senior Lecturer and Team Leader
Institute of Cancer


Overall research programme:

Professor Lemoine is the Director of both the Institute of Cancer and the Cancer Research UK Clinical Centre. He also leads the Centre for Molecular Oncology, where the research of four groups focuses on the molecular pathology of solid malignancies, gene transcription biology, cell survival signalling, and molecular therapeutics including gene therapy and vaccine approaches.
The Centre for Molecular Oncology aims to exploit the technologies of functional genomics to develop novel approaches for diagnosis, classification and treatment of human cancers. Advances in knowledge resulting from the sequencing of the human genome and the advent of high-throughput technologies now facilitate simultaneous analysis of the activity of many genes in cells and tissues, and the challenge is to translate such molecular profiles into clinical benefit for patients.

The main research interest of Dr Crnogorac-Jurcevic is to understand the molecular genetics of pancreatic cancer, particularly the earliest molecular changes in the development of this malignancy by utilising large-scale transcriptomic and proteomic analyses. She hopes to find a minimal set of biomarkers that will enable an early detection of pancreatic cancer with high levels of specificity and sensitivity at the stage when curative surgery is still possible. In addition to tissues, a particular focus in her work is the analysis of body fluids (plasma and urine), which will enable non-invasive diagnosis and monitoring of patients with this malignancy.
The second aspect of her studies is based on uncovering molecular signatures of micrometastatic disease. Thus selected genes/proteins would represent a target for novel therapeutics that could be used in conjunction with surgical treatment.


Role in the Integrated Project:

We are coordinating WP2 (Molecular alterations of preneoplastic lesions, early and advanced tumours: genomic, transcriptomic and proteomic profiles) and are also involved in WP1 (Epidemiology and patient resources), WP3 (RNA-based diagnostics), WP4 (Proteome based diagnostics) and WP6 (Molecular Imaging tools).


Group members involved:

  • Dr Tomohiko Harada
  • Dr Mark Weeks
  • Dr Deepak Hariharan
  • Tomasz Radon


Contact:

Molecular Oncology Unit, Institute of Cancer,
John Vane Science Centre, Charterhouse Square,
London EC1M 6BQ,
United Kingdom
Tel +44 (0)20 7014 0420
Fax +44 (0)20 7014 0461
http://www.cancer.qmul.ac.uk/


>> Publications

Tartu, Estonia


Asper Biotech is a leading Estonian biotechnology company established in 1999. From this time Asper has grown to become the biggest biotech exporter in Estonia with a series of well-established robust and efficient DNA tests. Our platform is based on the arrayed primer extension (APEX) technology that combines the efficiency of a microarray-based assay with the Sanger sequencing. The main offerings include custom genotyping services, genotyping software, genotyping hardware, and genotyping consumables. Asper`s business model is conducting research projects for the world`s science, research and development organisations. During the seven years, Asper has developed its expertise in developing and validating highly customised SNP/mutation screening assays. After establishing the tests, DNA samples screening will be performed. Bioinformatics expertise allows us carefully design all the assays as well as analyse and validate the results. Together with our partners, we have developed and launched a number of DNA tests like Thalassemia, p53 gene testing, Cystic Fibrosis, Hereditary Hearing Loss, DNA Repair, and eye diseases related tests: ABCR, LCA, Usher, AR-RP, AD-RP, BBS. The list of the assays will be expanded during the next years. The strong scientific relevance and professional approach to its business become obvious also from our participation in several European Commission projects: from 30 proposals of FP6 in which Asper Biotech has been involved, six have been financed during the calls 1-3. Additional info about our tests and technology can be obtained by visiting our website http://www.asperbio.com.


Role of Asper Biotech in the project MolDiag-Paca
Asper Biotech will be involved in the Epigenetics Workpackage No 5. The role of Asper includes:
  • Working APEX assay with 275 markers on the chip
  • Analysis of DNA samples separated from 300 patients


Group members involved
  • Mikk Tamme – managing director
  • Dr. Katrin Sak – senior researcher


Contact data
Asper Biotech
Oru 3
51014 Tartu
Estonia
Telefon: +372 7 441 556; +372 7 441 772
Telefax: +372 7 442 343
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


>> Publications


Prof. Dr. Helmut Friess, (Key person 1): Chairman, Department of Surgery; expertise in high-throughput analysis, randomized controlled clinical studies

Dr. Jörg Kleeff (Key person 2): Surgeon; expertise in high-throughput analysis, tissues collection/archiving, randomized controlled clinical studies
Dr. Christoph W. Michalski: Surgical resident and postdoctoral research fellow with experience in tissue collection/archiving, database management, randomized controlled clinical studies


Research Focus
The Department of General Surgery at the Technische Universität München, Munich, Germany is one of the leading centers for pancreatic surgery and clinical as well as basic research in Europe. Tissue and serum samples are routinely obtained from pancreatic cancer patients following written informed consent. All studies have been approved by the local Ethics Committee and are carried out according to the current version of the Declaration of Helsinki (1996). The tissue and serum bank at the Department of Surgery comprises more than 500 well documented cases of pancreatic tumours. The molecular biology research laboratory as part of the Department of General Surgery has a renowned track record of pancreatic research. High throughput analysis such as DNA microarrays have been employed for the detection of diagnostic tools and/or molecular targets in pancreatic diseases. Having one of the largest collections of high quality tissue specimen, candidate genes are currently being investigated on a broad scale (see relevant publications). Parts of the studies are conducted in close collaborations with partners at the GSF - National Research Center for Environment and Health (www.gsf.de) and at the German Cancer Research Center, Heidelberg (DKFZ, www.dkfz.de). In addition, a clinical trial centre (Chir-Net) has been established at the Department of General Surgery with full-time working physicians, study nurses and secretaries. This infrastructure allows for the rapid clinical testing of new diagnostic and therapeutic modalities in pancreatic cancer.